Have you been diagnosed with cITP?
Ask your doctor about proven results with PANZYGA
PANZYGA is an FDA-approved treatment that was studied in a clinical trial for adults with cITP where it was shown to boost platelet counts.
Explore these helpful topics to see if PANZYGA can help you on your treatment journey with cITP.
What is cITP?
Chronic immune thrombocytopenia (cITP) is a rare autoimmune disorder that can lead to excessive bruising or bleeding.
What is cITP?
Chronic immune thrombocytopenia (cITP) is a rare autoimmune disorder that can lead to excessive bruising or bleeding.
What causes cITP?
Patients with cITP have low levels of certain blood cells called platelets, which are essential to helping the blood to clot. This condition is caused by your own immune system attacking the platelets in your blood, which is why it is called an autoimmune disorder. ITP is considered chronic when it lasts for more than 12 months.
Symptoms of cITP
Symptoms of cITP vary greatly between individuals and the severity of your condition. Signs of bleeding may include:
- Petechiae (pe-TEEK-ee-ay), small, flat red dots on the skin caused by blood leaking from blood vessels
- Purpura, which is bleeding under your skin that can cause red, purple, or brownish-yellow spots
- Clotted or partially clotted blood under your skin (called a hematoma) that looks or feels like a lump
- Nosebleeds or bleeding from your gums
- Blood in urine or stools
- Heavy menstrual bleeding
- Extreme tiredness
- Pale skin color, dizziness, and tiredness if bleeding causes anemia
PANZYGA showed proven results in a clinical trial
In the trial, 40 adult patients with cITP received PANZYGA to see how well patients responded to treatment with PANZYGA. Patients were given a 2 g/kg dose of PANZYGA through an IV, which was divided into two equal doses, given on 2 consecutive days. The 36 patients that were able to receive a second treatment were analyzed in the final results.
PANZYGA helped increase the number of platelets
81% of patients
(29 out of 36)
saw an increase
in platelet counts
within 7 days
after their first infusion
The rise in platelets for those patients who responded to PANZYGA happened in about 2 days, and lasted for 14 days
PANZYGA also helped to decrease bleeding
The percentage of patients with bleeding went down from 64% before the trial, to 14% after 7 days in the study
Most common side effects
In the clinical trial, more than 5% of patients experienced these side effects:
- Headache: 50%
- Fever: 23%
- Nausea: 18%
- Vomiting: 10%
- Dizziness: 10%
- Anemia: 10%
*Eligible, commercially insured patients may receive a maximum benefit of $12,500 per year or the cost of a patient’s co-pay in a 12-month period (whichever is less) for claims received by the program. No membership fees are required. Federal and state healthcare beneficiaries are not eligible. The PANZYGA Co-Pay Program is good only in the US and Puerto Rico. Terms and conditions/eligibility requirements apply. See full Terms and Conditions on the Financial assistance programs page.
Want to connect with other patients diagnosed with cITP?
The Platelet Disorder Support Association offers education and support to individuals and families affected by cITP
